Page 2 - Abclonal Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ABclonal Technology products, product reviews and application articles on SelectScience.

The mechanism by which the LNC00115/miR-7/ERK axis promotes cisplatin resistance provides a new strategy for combating cisplatin resistance in ovarian cancer

Published: Mar 05, 2021 By Mark Terry Boston-based ABclonal Biotechnology acquiredcontract research organization (CRO) Yurogen Biosystems, headquartered in nearby Worcester, Massachusetts. Yurogen focuses on producing antibodies and antibody-based products for its clients. Its technology platform is a monoclonal antibody discovery program using single-B-cell-based SMab. This technology platform allows for high-throughput development of high-affinity, high-specificity monoclonal antibodies. No financial details were disclosed. Late in February, ABclonal, which calls itself a global li...

ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide News provided by Share this article Share this article BOSTON, March 5, 2021 /PRNewswire/ -- ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMab TM platform, to better serve researchers in in vitro diagnostic, and antibody drug and therapeutic discovery markets worldwide. The acquisition comes after the c...

/PRNewswire/ -- ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by...